Chemokines after human ischemic stroke: From neurovascular unit to blood using protein arrays

Translational Proteomics

Volumn 3, Issue 1, 2014, Pages 1-9

  García Berrocoso, Teresa ^a   Giralt, Dolors ^a   Llombart, Víctor ^a   Bustamante, Alejandro ^a   Penalba, Anna ^a   Flores, Alan ^b   Ribó, Marc ^b   Molina, Carlos A ^b   Rosell, Anna ^a   Montaner, Joan ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Biomarker; CCL22; Chemokines; Ischemic stroke; Microdissection; Temporal profile

Indexed keywords

CCL1 CHEMOKINE; CHEMOKINE; EOTAXIN; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ARTICLE; BRAIN BLOOD VESSEL; BRAIN CELL; BRAIN ISCHEMIA; BRAIN LEVEL; CELL LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER MICRODISSECTION; MOLECULAR PATHOLOGY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CELL LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN MICROARRAY;

EID: 84994389261     PISSN: 22129626     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trprot.2014.03.001     Document Type: Article

References (76)

1. Mehta S.L., Manhas N., Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Research Reviews 2007, 54:34-66. 10.1016/j.brainresrev.2006.11.003.
2. Barone F.C., Feuerstein G.Z. Inflammatory mediators and stroke: new opportunities for novel therapeutics. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 1999, 19:819-834. http://www.ncbi.nlm.nih.gov/pubmed/.
3. Ceulemans A.G., Zgavc T., Kooijman R., Hachimi-Idrissi S., Sarre S., Michotte Y. The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia. Journal of Neuroinflammation 2010, 7:74. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1186/1742-2094-7-74.
4. Kochanek P.M., Hallenbeck J.M. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke: A Journal of Cerebral Circulation 1992, 23:1367-1379. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1161/01.STR.23.9.1367.
5. del Zoppo G.J. Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience 2009, 158:972-982. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.neuroscience.2008.08.028.
6. Mackay C.R. Chemokines: immunology's high impact factors. Nature Immunology 2001, 2:95-101. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1038/84298.
7. Rosell A., Ortega-Aznar A., Alvarez-Sabín J., Fernández-Cadenas I., Ribó M., Molina C.A., et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke: A Journal of Cerebral Circulation 2006, 37:1399-1406. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1161/01.STR.0000223001.06264.af.
8. Montaner J., Chacón P., Krupinski J., Rubio F., Millán M., Molina C.A., et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 2008, 15:82-90. http://www.ncbi.nlm.nih.gov/pubmed/.
9. Brott T., Bogousslavsky J. Treatment of acute ischemic stroke. New England Journal of Medicine 2000, 343:710-722. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1056/NEJM200009073431007.
10. Brott T.G., Haley E.C., Levy D.E., Barsan W., Broderick J., Sheppard G.L., et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke: A Journal of Cerebral Circulation 1992, 23:632-640. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1161/01.STR.23.5.632.
11. Cuadrado E., Rosell A., Penalba A., Slevin M., Alvarez-Sabín J., Ortega-Aznar A., et al. Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. Journal of Proteome Research 2009, 8:3191-3197. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1021/pr801012x.
12. Tuttolomondo A., Di Raimondo D., di Sciacca R., Pinto A., Licata G. Inflammatory cytokines in acute ischemic stroke. Current Pharmaceutical Design 2008, 14:3574-3589. http://www.ncbi.nlm.nih.gov/pubmed/, 10.2174/138161208786848739.
13. Jaerve A., Müller H.W. Chemokines in CNS injury and repair. Cell and Tissue Research 2012, 349:229-248. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1007/s00441-012-1427-3.
14. Biber K., Zuurman M.W., Dijkstra I.M., Boddeke H.W.G.M. Chemokines in the brain: neuroimmunology and beyond. Current Opinion in Pharmacology 2002, 2:63-68. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/S1471-4892(01)00122-9.
15. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. Journal of Immunology (Baltimore, MD: 1950) 2004, 172:2731-2738. http://www.ncbi.nlm.nih.gov/pubmed/.
16. Shibata K., Nomiyama H., Yoshie O., Tanase S. Genome diversification mechanism of rodent and Lagomorpha chemokine genes. BioMed Research International 2013, 2013:856265. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1111/j.1365-2249.2008.03650.x.
17. Ambrosini E., Columba-Cabezas S., Serafini B., Muscella A., Aloisi F. Astrocytes are the major intracerebral source of macrophage inflammatory protein-3alpha/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro. Glia 2003, 41:290-300. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1002/glia.10193.
18. Mantovani A., Gray P.A., Van Damme J., Sozzani S. Macrophage-derived chemokine (MDC). Journal of Leukocyte Biology 2000, 68:400-404. http://www.ncbi.nlm.nih.gov/pubmed/.
19. Imai T., Nagira M., Takagi S., Kakizaki M., Nishimura M., Wang J., et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. International Immunology 1999, 11:81-88. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1093/intimm/11.1.81.
20. Theodorou G.L., Marousi S., Ellul J., Mougiou A., Theodori E., Mouzaki A., et al. T helper 1 (Th1)/Th2 cytokine expression shift of peripheral blood CD4+ and CD8+ T cells in patients at the post-acute phase of stroke. Clinical and Experimental Immunology 2008, 152:456-463. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1111/j.1365-2249.2008.03650.x.
21. Dirnagl U., Klehmet J., Braun J.S., Harms H., Meisel C., Ziemssen T., et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke: A Journal of Cerebral Circulation 2007, 38:770-773. http://www.ncbi.nlm.nih.gov/pubmed/.
22. Becker K.J. Modulation of the postischemic immune response to improve stroke outcome. Stroke: A Journal of Cerebral Circulation 2010, 41:S75-S78. http://www.ncbi.nlm.nih.gov/pubmed/.
23. Chan A.C., Carter P.J. Therapeutic antibodies for autoimmunity and inflammation. Nature Reviews. Immunology 2010, 10:301-316. http://www.ncbi.nlm.nih.gov/pubmed/.
24. Sudduth T.L., Schmitt F.A., Nelson P.T., Wilcock D.M. Neuroinflammatory phenotype in early. Alzheimer's disease. Neurobiology of Aging 2013, 34:1051-1059.
25. Losy J., Zaremba J. Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke. Stroke: A Journal of Cerebral Circulation 2001, 32:2695-2696. http://www.ncbi.nlm.nih.gov/pubmed/.
26. Sánchez-Moreno C., Dashe J.F., Scott T., Thaler D., Folstein M.F., Martin A. Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke: A Journal of Cerebral Circulation 2004, 35:163-168. http://www.ncbi.nlm.nih.gov/pubmed/.
27. Arakelyan A., Petrkova J., Hermanova Z., Boyajyan A., Lukl J., Petrek M. Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators of Inflammation 2005, 2005:175-179. http://www.ncbi.nlm.nih.gov/pubmed/.
28. Zaremba J., Ilkowski J., Losy J. Serial measurements of levels of the chemokines CCL2, CCL3 and CCL5 in serum of patients with acute ischaemic stroke. Folia Neuropathologica/Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences 2006, 44:282-289. http://www.ncbi.nlm.nih.gov/pubmed/.
29. Chen S., Martens-Lobenhoffer J., Weissenborn K., Kielstein J.T., Lichtinghagen R., Deb M., et al. Association of dimethylarginines and mediators of inflammation after acute ischemic stroke. Journal of Neuroinflammation 2012, 9:251. http://www.ncbi.nlm.nih.gov/pubmed/.
30. Worthmann H., Tryc A.B., Goldbecker A., Ma Y.T., Tountopoulou A., Hahn A., et al. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovascular Diseases (Basel, Switzerland) 2010, 30:85-92. http://www.ncbi.nlm.nih.gov/pubmed/.
31. Kuriyama N., Mizuno T., Kita M., Nagakane Y., Hosomi A., Harada S., et al. Predictive markers of blood cytokine and chemokine in recurrent brain infarction. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research 2009, 29:729-734. http://www.ncbi.nlm.nih.gov/pubmed/.
32. Alvarez-Sabín J., Penalba A., Quintana M., Krupinski J., García-Bonilla L., Montaner J. Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke. Cerebrovascular Diseases (Basel, Switzerland) 2009, 28:371-377. http://www.ncbi.nlm.nih.gov/pubmed/.
33. Yamagami S., Tamura M., Hayashi M., Endo N., Tanabe H., Katsuura Y., et al. Differential production of MCP-1 and cytokine-induced neutrophil chemoattractant in the ischemic brain after transient focal ischemia in rats. Journal of Leukocyte Biology 1999, 65:744-749. http://www.ncbi.nlm.nih.gov/pubmed/.
34. Jiang L., Newman M., Saporta S., Chen N., Sanberg C., Sanberg P.R., et al. MIP-1alpha and MCP-1 induce migration of human umbilical cord blood cells in models of stroke. Current Neurovascular Research 2008, 5:118-124. http://www.ncbi.nlm.nih.gov/pubmed/.
35. Schilling M., Strecker J.K., Schabitz W.R., Ringelstein E.B., Kiefer R. Effects of monocyte chemoattractant protein 1 on bloodborne cell recruitment after focal cerebral ischemia in mice. Neurosciences 2009, 161:806-812.
36. Strecker J.K., Minnerup J., Gess B., Ringelstein E.B., Schäbitz W.R., Schilling M. Monocyte chemoattractant protein-1-deficiency impairs the expression of IL-6, IL-1β and G-CSF after transient focal ischemia in mice. PLoS ONE 2011, 6:e25863. http://www.ncbi.nlm.nih.gov/pubmed/.
37. Strecker J.K., Minnerup J., Schütte-Nütgen K., Gess B., Schäbitz W.R., Schilling M. Monocyte chemoattractant protein-1-deficiency results in altered blood-brain barrier breakdown after experimental stroke. Stroke: A Journal of Cerebral Circulation 2013, 44:2536-2544. http://www.ncbi.nlm.nih.gov/pubmed/.
38. Chen Y., Hallenbeck J.M., Ruetzler C., Bol D., Thomas K., Berman N.E.J., et al. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2003, 23:748-755. http://www.ncbi.nlm.nih.gov/pubmed/.
39. Yan Y.P., Sailor K.A., Lang B.T., Park S.W., Vemuganti R., Dempsey R.J. Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2007, 27:1213-1224. http://www.ncbi.nlm.nih.gov/pubmed/.
40. Andres R.H., Choi R., Pendharkar A.V., Gaeta X., Wang N., Nathan J.K., et al. The CCR2/CCL2 interaction mediates the transendothelial recruitment of intravascularly delivered neural stem cells to the ischemic brain. Stroke: A Journal of Cerebral Circulation 2011, 42:2923-2931. http://www.ncbi.nlm.nih.gov/pubmed/.
41. Stowe A.M., Wacker B.K., Cravens P.D., Perfater J.L., Li M.K., Hu R., et al. CCL2 upregulation triggers hypoxic preconditioning-induced protection from stroke. Journal of Neuroinflammation 2012, 9:33. http://www.ncbi.nlm.nih.gov/pubmed/.
42. Slevin M., Krupinski J., Rovira N., Turu M., Luque A., Baldellou M., et al. Identification of pro-angiogenic markers in blood vessels from stroked-affected brain tissue using laser-capture microdissection. BMC Genomics 2009, 10:113. http://www.ncbi.nlm.nih.gov/pubmed/.
43. Dimitrijevic O.B., Stamatovic S.M., Keep R.F., Andjelkovic A.V. Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2006, 26:797-810. http://www.ncbi.nlm.nih.gov/pubmed/.
44. Che X., Ye W., Panga L., Wu D.C., Yang G.Y. Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Research 2001, 902:171-177. http://www.ncbi.nlm.nih.gov/pubmed/.
45. Montecucco F., Lenglet S., Gayet-Ageron A., Bertolotto M., Pelli G., Palombo D., et al. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke: A Journal of Cerebral Circulation 2010, 41:1394-1404. http://www.ncbi.nlm.nih.gov/pubmed/.
46. Küry P., Schroeter M., Jander S. Transcriptional response to circumscribed cortical brain ischemia: spatiotemporal patterns in ischemic vs. remote non-ischemic cortex. European Journal of Neuroscience 2004, 19:1708-1720. http://www.ncbi.nlm.nih.gov/pubmed/.
47. Takami S., Minami M., Nagata I., Namura S., Satoh M. Chemokine receptor antagonist peptide, viral MIP-II, protects the brain against focal cerebral ischemia in mice. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2001, 21:1430-1435. http://www.ncbi.nlm.nih.gov/pubmed/.
48. Bona E., Andersson A.L., Blomgren K., Gilland E., Puka-Sundvall M, Gustafson K, et al. Chemokine and inflammatory cell response to hypoxia-ischemia in immature rats. Pediatric Research 1999, 45:500-509. http://www.ncbi.nlm.nih.gov/pubmed/.
49. Ramos-Cejudo J., Gutiérrez-Fernández M., Rodríguez-Frutos B., Expósito Alcaide M., Sánchez-Cabo F., Dopazo A., et al. Spatial and temporal gene expression differences in core and periinfarct areas in experimental stroke: a microarray analysis. PLoS ONE 2012, 7:e52121. http://www.ncbi.nlm.nih.gov/pubmed/.
50. Wang J., Li P.T., Du H., Hou J.C., Li W.H., Pan Y.S., et al. Tong Luo Jiu Nao injection, a traditional Chinese medicinal preparation, inhibits MIP-1β expression in brain microvascular endothelial cells injured by oxygen-glucose deprivation. Journal of Ethnopharmacology 2012, 141:151-157. http://www.ncbi.nlm.nih.gov/pubmed/.
51. Terao S., Yilmaz G., Stokes K.Y., Russell J., Ishikawa M., Kawase T., et al. Blood cell-derived RANTES mediates cerebral microvascular dysfunction, inflammation, and tissue injury after focal ischemia-reperfusion. Stroke: A Journal of Cerebral Circulation 2008, 39:2560-2570. http://www.ncbi.nlm.nih.gov/pubmed/.
52. Wang X., Li X., Yaish-Ohad S., Sarau H.M., Barone F.C., Feuerstein G.Z. Molecular cloning and expression of the rat monocyte chemotactic protein-3 gene: a possible role in stroke. Brain Resources: Molecular Brain Research 1999, 71:304-312.
53. White R.E., Palm C.J., Xu L., Ling E.B., Ginsburg M., Daigle B.J., et al. Mice lacking the β2 adrenergic receptor have a unique genetic profile before and after focal brain ischemia. ASN Neuro 2012, 4:e00096.
54. Ohta H., Terao Y., Shintani Y., Kiyota Y. Therapeutic time window of post-ischemic mild hypothermia and the gene expression associated with the neuroprotection in rat focal cerebral ischemia. Neuroscience Research 2007, 57:424-433. http://www.ncbi.nlm.nih.gov/pubmed/.
55. Terao Y., Ohta H., Oda A., Nakagaito Y., Kiyota Y., Shintani Y. Macrophage inflammatory protein-3alpha plays a key role in the inflammatory cascade in rat focal cerebral ischemia. Neuroscience Research 2009, 64:75-82. http://www.ncbi.nlm.nih.gov/pubmed/.
56. Biber K., Sauter A., Brouwer N., Copray S.C., Boddeke H.W. Ischemia-induced neuronal expression of the microglia attracting chemokine secondary lymphoid-tissue chemokine (SLC). Glia 2001, 34:121-133. http://www.ncbi.nlm.nih.gov/pubmed/.
57. Losy J., Zaremba J., Skrobański P. CXCL1 (GRO-alpha) chemokine in acute ischaemic stroke patients. Folia Neuropathologica/Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences 2005, 43:97-102. http://www.ncbi.nlm.nih.gov/pubmed/.
58. Ormstad H., Aass H.C., Lund-Srensen N., Amthor K.F., Sandvik L. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. Journal of Neurology 2011, 258:677-685. http://www.ncbi.nlm.nih.gov/pubmed/.
59. Benakis C., Vaslin A., Pasquali C., Hirt L. Neuroprotection by inhibiting the c-Jun N-terminal kinase pathway after cerebral ischemia occurs independently of interleukin-6 and keratinocyte-derived chemokine (KC/CXCL1) secretion. Journal of Neuroinflammation 2012, 9:76. http://www.ncbi.nlm.nih.gov/pubmed/.
60. Copin J.C., da Silva R.F., Fraga-Silva R.A., Capettini L., Quintao S., Lenglet S., et al. Treatment with evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2013, 33:490-498. http://www.ncbi.nlm.nih.gov/pubmed/.
61. Tombul T., Atbas C., Anlar O. Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia 2005, 12:429-434. http://www.ncbi.nlm.nih.gov/pubmed/.
62. Kurabayashi H., Tamura J., Naruse T., Kubota K. Possible existence of platelet activation before the onset of cerebral infarction. Atherosclerosis 2000, 153:203-207. http://www.ncbi.nlm.nih.gov/pubmed/.
63. Zaremba J., Skrobański P., Losy J. The level of chemokine CXCL5 in the cerebrospinal fluid is increased during the first 24 hours of ischaemic stroke and correlates with the size of early brain damage. Folia Morphologica 2006, 65:1-5. http://www.ncbi.nlm.nih.gov/pubmed/.
64. Grau A.J., Reis A., Buggle F., Al-Khalaf A., Werle E., Valois N., et al. Monocyte function and plasma levels of interleukin-8 in acute ischemic stroke. Journal of the Neurological Sciences 2001, 192:41-47. http://www.ncbi.nlm.nih.gov/pubmed/.
65. Villa P., Triulzi S., Cavalieri B., Di Bitondo R., Bertini R., Barbera S., et al. The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Molecular Medicine (Cambridge, MA) 2007, 13:125-133. http://www.ncbi.nlm.nih.gov/pubmed/.
66. Chaitanya G.V., Eeka P., Munker R., Alexander J.S., Babu P.P. Role of cytotoxic protease granzyme-b in neuronal degeneration during human stroke. Brain Pathology (Zurich, Switzerland) 2011, 21:16-30. http://www.ncbi.nlm.nih.gov/pubmed/.
67. Kuboyama K., Harada H., Tozaki-Saitoh H., Tsuda M., Ushijima K., Inoue K. Astrocytic P2Y(1) receptor is involved in the regulation of cytokine/chemokine transcription and cerebral damage in a rat model of cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2011, 31:1930-1941. http://www.ncbi.nlm.nih.gov/pubmed/.
68. Wang X., Ellison J.A., Siren A.L., Lysko P.G., Yue T.L., Barone F.C., et al. Prolonged expression of interferon-inducible protein-10 in ischemic cortex after permanent occlusion of the middle cerebral artery in rat. Journal of Neurochemistry 1998, 71:1194-1204. http://www.ncbi.nlm.nih.gov/pubmed/.
69. Kim S.J., Moon G.J., Cho Y.H., Kang H.Y., Hyung N.K., Kim D., et al. Circulating mesenchymal stem cells microparticles in patients with cerebrovascular disease. PLoS ONE 2012, 7:e37036. http://www.ncbi.nlm.nih.gov/pubmed/.
70. Sobrino T., Pérez-Mato M., Brea D., Rodríguez-Yáñez M., Blanco M., Castillo J. Temporal profile of molecular signatures associated with circulating endothelial progenitor cells in human ischemic stroke. Journal of Neuroscience Research 2012, 90:1788-1793. http://www.ncbi.nlm.nih.gov/pubmed/.
71. Wurster T., Stellos K., Geisler T., Seizer P., Andia M.E., Schuster A., et al. Expression of stromal-cell-derived factor-1 (SDF-1): a predictor of ischaemic stroke?. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 2012, 19:395-401. http://www.ncbi.nlm.nih.gov/pubmed/.
72. Kim Y.S., Baek W., Kim M.K., Kim H.Y., Lee K.Y., Lee Y.J., et al. Association between serum stromal cell-derived factor-1α and long-term outcome of acute ischemic stroke. European Neurology 2012, 67:363-369. http://www.ncbi.nlm.nih.gov/pubmed/.
73. Stumm R.K., Rummel J., Junker V., Culmsee C., Pfeiffer M., Krieglstein J., et al. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2002, 22:5865-5878. http://www.ncbi.nlm.nih.gov/pubmed/.
74. Yoo J., Seo J.J., Eom J.H., Hwang D.Y. Effects of stromal cell-derived factor 1α delivered at different phases of transient focal ischemia in rats. Neuroscience 2012, 209:171-186. http://www.ncbi.nlm.nih.gov/pubmed/.
75. Wang K.D., Liu Z.Z., Wang R.M., Wang Y.J., Zhang G.J., Su J.R., et al. Chemokine CXC ligand 16 serum concentration but not A181V genotype is associated with atherosclerotic stroke. Clinica Chimica Acta: International Journal of Clinical Chemistry 2010, 411:1447-1451. http://www.ncbi.nlm.nih.gov/pubmed/.
76. Ueland T., Smedbakken L.M., Hallén J., Atar D., Januzzi J.L., Halvorsen B., et al. Soluble CXCL16 and long-term outcome in acute ischemic stroke. Atherosclerosis 2012, 220:244-249. http://www.ncbi.nlm.nih.gov/pubmed/.